Abstract
The mechanisms underlying increased thrombotic risk in chronic myeloproliferative neoplasms (MPN) are incompletely understood. We assessed whether neutrophil extracellular traps (NETs), which promote thrombosis, contribute to the procoagulant state in essential thrombocythemia, polycythemia vera and myelofibrosis (MF) patients. Although MPN neutrophils showed increased basal reactive oxygen species (ROS), enhanced NETosis by unstimulated neutrophils was an infrequent finding, whereas PMA-triggered NETosis was impaired, particularly in MF, due to decreased PMA-triggered ROS production. Elevated circulating nucleosomes were a prominent finding and were higher in patients with advanced disease, which may have potential prognostic implication. Histone-MPO complexes, proposed as specific NET biomarker, were seldomly detected, suggesting NETs may not be the main source of nucleosomes in most patients, whereas their correlation with high LDH points to increased cell turn-over as a plausible origin. Lack of association of nucleosomes or NETs with thrombosis or activation markers does not support their use as predictors of thrombosis although prospective studies in a larger cohort may help define their potential contribution to MPN thrombosis. These results do not provide evidence for relevant in vivo NETosis in MPN patients under steady state conditions, although availability of standardized NET biomarkers may contribute to further research in this field.
Similar content being viewed by others
Introduction
Classic BCR-ABL-negative chronic myeloproliferative neoplasms (MPN) are stem cell disorders characterized by abnormal myeloid proliferation and increased blood cell counts and comprise polycythemia vera (PV), essential thrombocythemia (ET) and primary myelofibrosis (PMF)1. Although PV, ET and PMF share several biological and molecular features, including the fundamental role of JAK/STAT signaling in disease pathogenesis, their clinical presentation and natural course show distinctive features. Whereas PV and ET tend to be indolent conditions with a relatively long life expectancy, survival in PMF is significantly worse and patients may develop progressive extramedullary hematopoiesis and increased rate of leukemic transformation1.
Thromboembolic complications represent a major cause of morbidity and mortality in MPN, particularly in PV and ET, but also, albeit less frequently recognized, in PMF2,3. Age >60 years, previous thrombosis and the JAK2V617F mutation are established risk factors for thrombosis and prove useful for risk stratification2. However, accurate prediction of the thrombotic risk still represents a challenge and adequate predictive biomarkers are not available. The mechanisms underlying thrombosis are incompletely understood and involve a complex interplay among blood cells, the endothelium and the coagulation system2. Both increased blood counts and cellular activation, which is due to hyperactivation of intracellular signaling pathways and enhanced interaction between blood cells, are implicated in the thrombotic predisposition. The key role of leukocytes in the pathogenesis of MPN thrombosis has been highlightened by several studies4,5,6,7. Ongoing neutrophil activation, evidenced by increased membrane CD11b, release of proteolytic enzymes and neutrophil/platelet aggregates, contributes to the procoagulant phenotype5,6. Although several markers of leukocyte and platelet activation have been linked to thrombosis development, their value as predictors of thrombosis has not been established. In addition, a systemic proinflammatory state coexists with the MPN clone8. A wide array of proinflammatory cytokines released by malignant and non-malignant cells are elevated in the bloodstream and may exacerbate the prothrombotic state by activating platelets, endothelial cells and leukocytes9.
In recent years, neutrophils have been shown to release neutrophil extracellular traps (NETs), which are weblike structures composed of DNA and histones associated with granular proteins that contribute to innate immunity by entrapping microorganisms10. During NETosis, neutrophils decondense their chromatin, the granular and nuclear contents are mixed and NETs are released to the extracellular space following desintegration of the cellular membrane11. Reactive oxygen species (ROS) generated by the NADPH oxidase complex mediate most forms of NETosis11. Besides microorganisms, NETs may be triggered by a variety of stimuli, including cytokines, such as tumor necrosis alpha (TNFα) and interleukin (IL)-810,11,12, activated platelets13,14 and autoantibodies15. Although primarily involved in host defense, NETs have been shown to promote thrombosis, as they provide suitable scaffolds for clot formation, binding red cells, platelets and von Willebrand factor (VWF), and induce a strong procoagulant response, mainly by contact phase activation and by enhancing tissue factor activity through elastase-mediated cleavage of tissue factor pathway inhibitor16,17. This process, which links innate immunity and thrombosis, has been named immunothrombosis18. The role of NETs in venous and arterial thrombosis has been demonstrated in animal models of experimental thrombosis19,20 and confirmed in human venous thromboembolism and coronary artery disease21,22, offering potential new targets for antithrombotic therapy. In this setting, circulating nucleosomes or cell-free DNA, presumed to originate from NETs, have been proposed as markers of thrombotic risk23.
Aside from their implication in thrombosis, excessive NET formation may trigger tissue damage and contribute to the pathogenesis of several disease states, as shown in sepsis24 and prothrombotic conditions characterized by sterile inflammation, such as systemic inflammatory response syndrome12, transfusion-related lung injury13, vasculitis15 and diabetes25. In addition, a role for NETs in neoplastic diseases has begun to be unraveled. Neutrophils from murine models of chronic myeloid leukemia, lung and breast cancer are sensitized towards NET generation26, suggesting NETs could be implicated in cancer-associated thrombosis.
Based on the presence of in vivo neutrophil activation in the setting of a chronic proinflammatory environment, we investigated whether NETs play a role in the thrombotic predisposition of MPN by studying the ability of MPN neutrophils to form NETs ex vivo and by measuring surrogate in vivo markers of NETosis.
Results
Patients
Patient features are detailed in Table 1 and reflect the variability in clinical phenotype found in daily clinical practice in patients with unselected PV, ET and myelofibrosis (MF), including primary, post-PV and post-ET MF. Plasma samples were available in 66 patients, including untreated patients and patients under different cytoreductive treatments, as detailed in Table 1. Assays involving neutrophils were performed in 32 of 66 patients, including untreated patients and patients treated with hydroxyurea. The number of patients included in each experiment is detailed where appropriate.
NET formation by MPN neutrophils in resting conditions
Based on the presence of neutrophil activation and increased thrombotic tendency, we determined whether MPN neutrophils were prone to release NETs spontaneously ex vivo by evaluating by microscopy NET production in the absence of NET inducers. NET formation by unstimulated neutrophils did not differ significantly between patients and controls (Fig. 1a). However, basal NET generation was heterogeneous among patients and increased NET release (higher than mean plus 2 SD of control values) was found in 6/32 (18.75%) patients, 2 with ET, 2 with PV and 2 with MF. Images from a patient with preserved and a patient with enhanced spontaneous NET formation are shown in Fig. 1b. Unstimulated NET formation did not differ significantly according to MPN phenotype (Fig. 1c), presence or absence of previous thrombosis (Fig. 1d) and mutational status (Fig. 1e). As hydroxyurea may inhibit certain neutrophil responses, such as P-selectin-induced tissue factor expression27, we reasoned that it could prevent the presence of spontaneous NETosis in MPN. However, comparison of hydroxyurea-treated vs. untreated patients revealed no significant differences (Fig. 1f), rendering this possibility unlikely. In addtion, although we previously demonstrated that aspirin inhibits NET formation in vitro28, no difference in spontaneous NETosis was found according to the use of low-dose aspirin (Supplementary Fig. 1S).
Basal reactive oxygen species production by MPN neutrophils
Increased ROS production induced by JAK2-dependent ERK constitutive phoshorylation and NADPH oxidase activation has been recently described in MPN neutrophils29. As ROS generation is a critical intermediate step in NET formation11, we assessed basal ROS production and analyzed its correlation with NETosis. The percentage of neutrophils with elevated ROS levels was increased in patients compared to controls (Fig. 2a,b), being higher in PV compared to ET and MF patients (Fig. 2c). ROS production in patients showed a bimodal distribution with a subset showing particularly high (>20%) levels. Interestingly, this group had higher leukocyte counts than those with ROS < 20%, 13.8 (7.5–23.1) vs. 6 (2.5–22.3) x109/L, P < 0.05. Of note, elevated ROS was not restricted to JAK2V617F+ patients, as previously reported29, but also involved CALR+ patients (Fig. 2d). Among patients with increased ROS, 27% had spontaneous NET formation compared to 10% of those with normal basal ROS, P = NS. The fact that only one third of patients with high basal ROS showed enhanced spontaneous NETosis suggests that under steady state conditions, higher levels of intracellular ROS or activation of additional signaling pathways are necessary to trigger NET release from MPN cells ex vivo.
NET generation in response to NET inducers
Next, we tested the ability of MPN neutrophils to form NETs when stimulated by inflammatory cytokines. Tumor necrosis factor α and IL-8 were used as proinflammatory mediators, as high plasma TNFα and IL-8 levels are prominent features in MPN8,30. Neutrophils from patients were able to release NETs when stimulated with TNFα and IL-8, and the response to these agents did not differ from controls (Fig. 3a), indicating that MPN cells do not show enhanced NETosis following cytokine stimulation. Considering that under our experimental conditions, TNFα and IL-8 proved to be relatively weak NET stimuli, we assessed the response to PMA, which represents a more potent NET inducer and has been extensively used to characterize NET formation in several disease states26,31,32. Although neutrophils from MPN patients were able to undergo NETosis when stimulated with PMA, this response was significantly reduced compared to controls, as evaluated by assessing the proportion of neutrophils undergoing NETosis by microscopy (Fig. 3a,b) and confirmed by quantification of DNA released to the supernatant by fluorometry (Fig. 3c). Correlation was found between these two methods of NET quantification, r = 0.77, P < 0.0001. Impaired PMA-triggered NETosis was most prominent in the subset of patients with MF, as demonstrated by both microscopy (Fig. 3d) and fluorometry (Fig. 3e). Altogether, these findings indicate that although MPN neutrophils are able to form NETs in response to proinflammatory stimuli, a defect in NET generation capacity is revealed when higher levels of NETosis are elicited by more potent inducers, such as PMA. Moreover, MF patients with impaired response to PMA showed a trend towards reduced response to PAF, a lipid mediator with a broad range of effects on the inflammatory response and strong NET inducer26,33, as revealed by quantification of released DNA (Fig. 3f) and shown in Fig. 3g.
ROS generation, ERK1/2 phosphorylation and CD11b upregulation triggered by phorbol esther stimulation
The signaling cascade underlying PMA-induced NET generation involves PKC-mediated activation of the Raf-MEK-ERK pathway leading to NADPH phosphorylation and ROS production34. To assess the mechanisms underlying decreased PMA-triggered NETosis, we measured ROS generation and ERK1/2 phosphorylation in response to this agent. Athough stimulation with 5 nM and 50 nM PMA increased ROS levels vs. baseline in all patients (P < 0.0001), those with marked impairment in PMA-induced NETosis (lower than mean minus 2 SD of control values) showed decreased ROS production in response to PMA, whereas ROS levels in patients with normal PMA-induced NETosis were preserved (Fig. 4a,b). These results indicate that low ROS generation capacity may contribute to defective PMA-triggered NET formation found in a subset of MPN patients. Reduced PMA-triggered ERK1/2 phosphorylation was observed in western blots from patients harbouring low PMA-induced NET and ROS generation, suggesting that the signal defect may lie upstream of ROS production. Interestingly, decreased ERK1/2 phosphorylation was not limited to patients with impaired NETosis but was also found in those with preserved NET formation, suggesting that other signaling molecules may compensate for altered ERK1/2 activation in these patients (Fig. 4c,d).
Besides triggering ROS and NET formation, PMA stimulates several other neutrophil functions, including degranulation. As described5,6, MPN neutrophils (n = 42) showed increased baseline CD11b expression, a marker of degranulation, compared to controls (n = 42); MFI was 24.3 (5.8–108.1) vs. 20.4 (9.5–96.5), P < 0.01 (Wilcoxon matched-pairs test). Upregulation of CD11b expression after exposure to 50 nM PMA was preserved in MPN (n = 32) vs. controls (n = 32); fold increase in MFI, 11.2 (2.2–42.9) vs. 12.6 (3.3–37.3), P = NS. Adequate CD11b upregulation was also shown for the subgroup of patients with reduced PMA-induced NETosis (n = 9) compared with simultaneousy assayed controls (n = 9); fold increase in MFI, 10.2 (6.1–17.1) vs. 11.8 (4.1–30.6), P = NS, indicating that, despite displaying lower levels of PMA-induced NETosis, neutrophil responses to PMA are not globally impaired.
Circulating nucleosomes in MPN patients
Considering that, in vivo, NET generation leads to release of DNA complexed with histones to the circulation, we measured plasma levels of nucleosomes, as an indirect measure of NETosis. Circulating nucleosomes were increased in patients compared with controls (Fig. 5a). Analysis of MPN subsets revealed that nucleosomes in all patient groups were significantly higher than in normal subjects; levels were moderately elevated in ET and PV and highest in MF (Fig. 5b). When categorized according to DIPSS Plus score35, patients with advanced MF had higher nucleosomes than those with early disease (Fig. 5c) and 3 of 9 patients harbouring levels higher than mean values for MF died within few months after analysis. Whereas no significant difference was found according to mutational status in ET, CALR+ MF patients showed a trend towards lower nucleosome levels than JAK2V617F+, 0.22 (0.07–0.71) μg/mL vs. 0.46 (0.08–1.58) μg/mL, P = 0.06 (Mann-Whitney test), probably because they tended to cluster in a lower DIPSS Plus category. Comparison of ET and PV patients treated versus those not treated with hydroxyurea revelead that nucleosomes were lower in those under cytoreductive therapy (Fig. 5d), whereas it was not possible to evaluate the effect of treatment in patients with MF owing to patient heterogeneity and the compound effect of risk category. Interestingly, a decline in nucleosome levels was evident in sequential samples from ruxolitinib-treated MF patients (Fig. 5e). No association was found between nucleosomes and the presence or absence of previous thrombosis (Fig. 5f). Levels of VWF antigen, circulating platelet-neutrophil aggregates and D-dimer were measured as markers of endothelial, cellular and coagulation activation. As reported5,6, increased VWF levels and platelet-neutrophil aggregates were found in this cohort, 7.95 (3.6–28.1) vs. 6.3 (2.4–12.9) μg/mL, P = 0.004 and 13.9 (1.5–58) vs. 9.7 (0–23.9)%, P = 0.009, respectively (Mann-Whitney test), whereas D-dimer levels were mildly but not significantly increased, 0.27 (0–1.6) vs 0.17 (0–0.51) μg/mL FEU, P = NS. No correlation was found between these activation markers and nucleosomes or NETs, P = NS for all correlations.
Plasma MPO, histone-MPO complexes and LDH levels
Based on the fact that elevated circulating nucleosomes were not associated with enhanced ex vivo NET formation and considering that nucleosomes may be originated by mechanisms other than NETosis, we measured plasma MPO, circulating histone-MPO complexes and LDH levels to gain further insight into the source of nucleosomes in MPN. MPO is a major granular protein which represents an integral NET component, although it may also be released as a result of neutrophil degranulation5. Plasma MPO was elevated in MPN compared with controls, 66.5 (13.9–379.3) vs 50.9 (17.5–61.9) ng/mL, P < 0.05 (Mann-Whitney test), and a certain degree of correlation was found between nucleosomes and both MPO and leukocyte counts (Fig. 6a,b). Recently, complexes of DNA or histones with granular proteins, including MPO or elastase, have been proposed as specific NET biomarkers13,15,36, although there are currently no available standardized assays for measurement of these complexes. Using a tailor-made capture ELISA, we determined histone-MPO complexes in plasma from patients harbouring the highest levels of nucleosomes. No evidence of histone-MPO complexes were found in most plasma samples except for two MF patients, whose levels were above cut-off values (Fig. 6c). The presence of histone-MPO complexes in these two MF patients was confirmed in a separate sample obtained several months apart. Interestingly, one of these patients had a history of prior thrombosis whereas the other had not experienced thrombotic events after a 4-year follow-up. Finally, a stronger positive association was found between nucleosomes and serum LDH, which may be released secondary to cell lysis (Fig. 6d). Altogether, this data suggest that, in most MPN patients, nucleosomes seem not be derived from NETs and that increased cell turn-over may represent a plausible factor contributing to extracellular DNA in this setting.
Discussion
Although largely beneficial as a host defense mechanism, excessive NETosis may trigger thrombosis and organ damage in diverse conditions characterized by acute or chronic inflammation. Several factors favouring NET release are present in MPN, including neutrophil activation5, cross-talk between neutrophils and activated platelets6 and a proinflammatory background, enriched in cytokines known to prime NETosis, such as TNFα and IL-88,30. Despite confirming the presence of neutrophil activation in this cohort, as evidenced by increased baseline CD11b, enhanced spontaneous ex vivo NET formation was not a frequent finding and remained limited to a subset of patients, who did not share distinctive clinical features. Excessive ROS production and oxidative stress have been shown to play a role in MPN pathogenesis37,38. In accordance with a recent study29, we confirmed that MPN neutrophils display increased basal ROS and extended this observation by showing that high ROS levels were not restricted to JAK2V617F+ patients, as described29, but also involved CALR+ patients. Whereas JAK2-dependent ERK phosphorylation and NADPH oxidase activation underlie ROS generation in JAK2V617F+ patients29, further study will determine whether upregulated JAK2 signaling, which also occurs in CALR+ patients39, is responsible for increased ROS in patients without the JAK2 mutation. Considering that ROS production is a key intermediate step in NET formation11, the fact that, in this study, high basal ROS levels were not uniformly associated with spontaneous NETosis, is intriguing. This may be in line with current data indicating that, although essential for NETosis, ROS production may not be sufficient in its own to trigger it and concomitant stimulation of additional signaling pathways is required40.
In this study, no significant differences in neutrophil responses, including NET and ROS generation and CD11b expression at baseline or in response to stimuli was found between untreated patients and those treated with hydroxyurea (as shown in Fig. 1f and Supplementary Table S1), indicating that although hydroxyurea may inhibit certain neutrophil functions27, these parameters were not significantly influenced by this cytoreductive treatment.
In an attempt to mimic the inflammatory mileu occurring in vivo, we next studied NET production after stimulation with TNFα and IL-8 and found that, in addition to the absence of spontaneous NETosis, patient neutrophils did not show hypersensitivity to these inflammatory mediators. Moreover, when challenged with a stronger NET inducer, such as PMA, MPN cells showed defective NET production. In particular, PMA-induced NETosis was significantly reduced in PV and MF, being most impaired in the latter, whereas the response in ET was preserved. This abnormality might represent an intrinsic cell defect, inherent to the abnormal MPN clone, or be acquired during circulation secondary to chronic in vivo activation and subsequent cell exhaustion. We showed that PMA-triggered ROS production was reduced in patients harbouring a profound impairment in NET formation, indicating that this defect lies, at least in part, at the step of ROS production, which may be due in turn to defective signals upstream of ROS, as suggested by the finding of reduced ERK1/2 phosphorylation. A more comprehensive study of other phagocytic functions may help determine whether neutrophil function is altered in MPN, particularly in MF patients, as suggested by previous findings41.
A major finding of this study was the presence of elevated circulating nucleosomes. Nucleosomes may be originated by NETosis or by other forms of cell death, such as necrosis or apoptosis42. The contribution of NETs to circulating nucleosomes in several clinical conditions is still a matter of debate. Several groups have relied on the identification of MPO or elastase attached to the DNA-histone backbone to establish whether nucleosomes are derived from NETs13,15,36. Histone-MPO complexes were present in a minority of patients in this cohort. Failure to detect these complexes in a large proportion of MPN samples raises the possibility that NETs may not be the main source of nucleosomes in most MPN patients. Therefore, although a few patients showed increased levels of histone-MPO complexes, absence of this feature in most studied patients does not provide evidence for a major role of NETosis in MPN, at least at steady state conditions. Alternatively, it might reflect the inability of the assay to detect lower levels of NETosis, as may occur in chronic conditions, as opposed to higher levels that may be found in acute states, such as septic shock. Availability of standardized methods for the identification of circulating NETs would help to definitively clarify this matter. Considering that clonal myeloid proliferation is a prominent feature of MPN, cell death secondary to increased turn-over may be another potential source of nucleosomes in this setting, as suggested by their association with high LDH. Along this line, elevated nucleosomes have been described in several malignant diseases, such as lymphoma and solid tumours43.
Regardless of their origin, nucleosomes may cause harmful effects. Both cell-free DNA and extracellular histones have been shown to activate coagulation, whereas histones may induce endothelial dysfunction and platelet activation44,45. Although nucleosomes might thus contribute to clot formation, the absence of correlation between nucleosome levels and previous thrombosis or activation markers does not seem to support the use of this parameter to predict thrombosis in MPN. However, this analysis might be limited by the relatively small size of the study population. Longitudinal prospective studies of larger patient cohorts would be required to establish this issue. Considering that, as shown in this work, cytoreductive treatment reduces nucleosome levels, analysis of samples from untreated patients would help to adequately address this matter.
Histones may, in addition, act as DAMPs to promote inflammation and cytokine release through toll-like receptor activation46, thus perpetuating the hyper-inflammatory state that characterizes MPN, particularly MF patients. We showed here that levels of nucleosomes varied according to MPN category, being highest in MF, particularly in those with high-risk features, indicating that nucleosomes may be a marker of advanced disease. Prospective studies in a larger MF cohort are necessary to assess the potential prognostic value of nucleosomes in the context of current risk stratification systems. Ruxolitinib has been show to ameliorate inflammation and decrease circulating cytokines in MPN patients47. Interestingly, in this study, a reduction in nucleosome levels was shown in sequential samples during ruxolitinib treatment, in parallel with clinical improvement and a decrease in C-reactive protein, a marker of inflammation.
In conclusion, our data show that neutrophils from MPN patients, despite displaying in vivo activation and increased basal ROS, are rarely prone to ex vivo NET generation and show, in fact, impaired PMA-induced NETosis, particularly in MF. In addition, the finding of elevated circulating nucleosomes was a prominent feature of this study, higher levels being associated with advanced disease, and may represent a potential prognostic marker. Overall, our results do not provide evidence for relevant in vivo NETosis under steady state conditions and suggest that increased cell turn-over might be a plausible source of nucleosomes in this setting. However, further research in this field and availability of standardized NET biomarkers may help establish this issue and define the potential contribution of NETs to MPN thrombosis.
Methods
Patients
Patients with MPN diagnosed according to the WHO criteria48, comprising ET, PV and primary, post-TE and post-PV myelofibrosis (MF), were included after written informed consent. Patients (n = 66) did not differ significantly from controls (n = 52) regarding age, 60 (19–86) vs. 56 (26–85) years old, and sex, 74 vs. 62%, respectively, were women. The study was approved by the Institute of Medical Research “Alfredo Lanari” Ethics Committee. All experiments were performed in accordance with relevant guidelines and regulations.
Sample preparation
After removal of platelet-rich plasma, neutrophils were purified by Ficoll-Hypaque gradient and dextran sedimentation, as described14. Plasma was obtained from EDTA-anticoagulated blood by two sequential centrifugation steps at 2500 × g for 15 minutes at 4 °C and stored at −70 °C.
NET formation by fluorescence microscopy
Neutrophils (2 × 105) were resuspended in RPMI 1640 supplemented with 0.5% fetal bovine serum, seeded in 24-well plates with polylysine-coated coverslips and incubated for 180 minutes, as described14, with or without 20 ng/mL TNFα (Peprotech, Rocky Hill, NJ, USA), 100 ng/mL IL-8 (Peprotech), 50 nM PMA (Enzo Life Sciences, Lausen, Switzerland) or 10 μM platelet-activating factor (PAF) (Sigma-Aldrich), fixed and permeabilized. After blocking with 5% goat serum, immunolabeling was performed with anti-neutrophil elastase rabbit pAb (Calbiochem, San Diego, CA, USA), followed by goat anti-rabbit IgG Alexa Fluor 488 (Life Technologies, Eugene, OR, USA) and Hoechst 33258 (Sigma-Aldrich, St. Louis, MO, USA). Images were acquired on an epifluorescent microscope (AXIOSTAR plus Zeiss, HAL 100, Göttingen, Germany). NETs were scored by two independent observers as clouds of DNA emanating from cells that stained positive for both neutrophil elastase and Hoechst and were at least twice as long as the cell diameter or neutrophils showing delobulated enlarged nuclei with conspicuous chromatin decondensation, an early sign of NETosis, as described26,31,34,49. Cells in at least 20 non-overlapping fields were counted for each condition and results were expressed as percentage of neutrophils forming NETs.
Fluorometry of released DNA in NET supernatants
In parallel experiments, neutrophils were placed in 24-well plates without coverslips and allowed to form NETs, as described14. After digestion with 500 mU/mL Micrococcal nuclease (Roche, Mannhein, Germany) for 15 minutes at 37 °C, 5 mM EDTA was added and supernatants were collected, centrifuged and stored at −20 °C. DNA was quantified with SYBR Gold (Invitrogen, Carlsbad, CA, USA) in a fluorometer (BioTek Instruments, Winooski, VT, USA). The calibration curve was constructed using thymus DNA of a known concentration.
Flow cytometry
To measure ROS levels, neutrophils were labeled with 5 μM dihydrorhodamine (Sigma-Aldrich) and incubated with or without PMA at 37 °C for 30 minutes. To assess CD11b expression and platelet-neutrophil aggregates, leukocytes in PBS-diluted blood were labeled with fluorescein isothiocyanate-conjugated anti-CD45 and phycoerythin-conjugated anti-CD11b or -CD41 antibodies (Biolegend San Diego, CA, USA), or corresponding isotype controls, during 15 min. with or without 50 nM PMA. Cells were analyzed in a flow cytometer. The neutrophil population was selected based on CD45 expression and side scatter (SSC) and platelet-neutrophil aggregates were identified as the percentage of events staining positive for CD41. Baseline CD11b was calculated as the ratio between mean fluorescence intensity (MFI) of antibody staining and the isotypic control. Fold-increase in CD11b was defined as the ratio between MFI of the stimulated sample minus baseline CD11b and baseline CD11b.
ERK1/2 phosphorylation by Western blot
Neutrophils (6 × 106) were incubated with or without PMA for 45 minutes at 37 °C, lysates were prepared with RIPA buffer and 40 μg proteins were resolved by SDS-PAGE. Immunoblotting was performed with mouse anti- p-ERK1/2 (Tyr 204) (Santa Cruz Biotechnology, Dallas, TX, USA) and protein loading was assessed with rabbit anti-ERK1/2 followed by the corresponding HRP-conjugated secondary antibodies and detection by enhanced chemiluminiscence.
Quantification of nucleosomes, circulating myeloperoxidase (MPO), histone-MPO complexes, VWF and D-dimer levels
Nucleosomes were measured in plasma using Cell Death Detection ELISA (Roche). A standard curve was prepared by making serial dilutions of a DNA-histone complex of a known concentration, supplied by the manufacturers. MPO levels were determined by LEGEND MAX™ ELISA (Biolegend) and histone-MPO complexes by ELISA, as described50, with modifications. Briefly, biotinylated anti-histone antibody (1:25 dilution) was added to streptavidin-coated plates (Cell Death Detection) and incubated during 2 hours. After blocking with 2.5% bovine serum albumin, plasma samples (1:4 dilution) were incubated during 2 hours followed by 2-hour incubation with HRP-conjugated anti-MPO antibody (Quantikine ELISA Human MPO, R&D, Minneapolis, MN, USA) and addition of tetramethylbenzidine, all at room temperature. Identical procedure was carried out for each sample omitting the anti-histone antibody. Absorbance at 450-nm wavelength of samples without anti-histone antibody (non-specific signal) was substracted from that of duplicate samples with anti-histone antibody (histone-MPO complexes). Supernatant of PMA-stimulated and unstimulated neutrophils was used as positive and negative control for NETosis, respectively. Antigen levels of VWF were measured by ELISA, as described51 and D-dimer by immunoturbidimetric assay (Innovance D-dimer, Siemens, Erlanger, Germany).
Statistical analysis
Data were tested for Gaussian distribution. For comparison between two groups, unpaired Student´s t-test was used for normally distributed data and Mann-Whitney test was applied for non-normally distributed data. For comparison among multiple groups, ANOVA with Tukey´s post-test or Kruskal-Wallis with Dunn´s post-test were used in case data followed a normal or non-normal distribution, respectively. Student´s paired t-test or Wilcoxon matched pairs test were applied for analysis of control and patient samples assayed simultaneously, according to whether or not variables followed a Gaussian distribution, respectively. Categorical values were examined by Fisher´s exact test and correlations with the Spearman correlarion test. All statistical analyses were two-sided and P values < 0.05 were considered significant. The GraphPad Prism 6.01 (La Jolla, CA, USA) software was applied.
Additional Information
How to cite this article: Marin Oyarzún, C. P. et al. Neutrophil extracellular trap formation and circulating nucleosomes in patients with chronic myeloproliferative neoplasms. Sci. Rep. 6, 38738; doi: 10.1038/srep38738 (2016).
Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
References
Tefferi, A. & Pardanani, A. Myeloproliferative neoplasms: a contemporary review. JAMA Oncol. 1, 97–105 (2015).
Barbui, T., Finazzi, G. & Falanga, A. Myeloproliferative neoplasms and thrombosis. Blood 122, 2176–2184 (2013).
Barbui, T. et al. Disease characteristics and clinical outcome in young adults with essential hrombocythemia versus early/prefibrotic primary myelofibrosis. Blood 120, 569–571 (2012).
Carobbio, A. et al. Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors, and Jak2 mutation status. Blood 109, 2310–2313 (2007).
Falanga, A. et al. Polymorphonuclear leukocyte activation and hemostasis in patients with essential thrombocythemia and polycythemia vera. Blood 96, 4261–4266 (2000).
Arellano-Rodrigo, E. et al. Increased platelet and leukocyte activation as contributing mechanisms for thrombosis in essential thrombocythemia and correlation with the JAK2 mutational status. Haematologica 91, 169–175 (2006).
Goette, N. P. et al. Monocyte IL-2Ralpha expression is associated with thrombosis and the JAK2V617F mutation in myeloproliferative neoplasms. Cytokine 51, 67–72 (2010).
Tefferi, A. et al. Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study. J Clin Oncol 29, 1356–1363 (2011).
Falanga, A. & Marchetti, M. Thrombotic disease in the myeloproliferative neoplasms. Hematology Am Soc Hematol Educ Program 2012, 571–581 (2012).
Brinkmann, V. et al. Neutrophil extracellular traps kill bacteria. Science 303, 1532–1535 (2004).
Fuchs, T. A. et al. Novel cell death program leads to neutrophil extracellular traps. J Cell Biol 176, 231–241 (2007).
Keshari, R. S. et al. Cytokines induced neutrophil extracellular traps formation: implication for the inflammatory disease condition. PLoS One 7, e48111 (2012).
Caudrillier, A. et al. Platelets induce neutrophil extracellular traps in transfusion-related acute lung injury. J Clin Invest 122, 2661–2671 (2012).
Carestia, A. et al. Mediators and molecular pathways involved in the regulation of neutrophil extracellular trap formation mediated by activated platelets. J Leukoc Biol 99, 153–162 (2016).
Kessenbrock, K. et al. Netting neutrophils in autoimmune small-vessel vasculitis. Nat Med; 15, 623–625 (2009).
Fuchs, T. A. et al. Extracellular DNA traps promote thrombosis. Proc Natl Acad Sci USA 107, 15880–15885 (2010).
Martinod, K. & Wagner, D. D. Thrombosis: tangled up in NETs. Blood 123, 2768–2776 (2014).
Engelmann, B. & Massberg, S. Thrombosis as an intravascular effector of innate immunity. Nat Rev Immunol 13, 34–45 (2013).
Brill, A. et al. Neutrophil extracellular traps promote deep vein thrombosis in mice. J Thromb Haemost 10, 136–144 (2012).
Savchenko, A. S. et al. VWF-mediated leukocyte recruitment with chromatin decondensation by PAD4 increases myocardial ischemia/reperfusion injury in mice. Blood 123, 141–148 (2014).
Savchenko, A. S. et al. Neutrophil extracellular traps form predominantly during the organizing stage of human venous thromboembolism development. J Thromb Haemost 12, 860–870 (2014).
de Boer, O. J. et al. Neutrophils, neutrophil extracellular traps and interleukin-17 associate with the organisation of thrombi in acute myocardial infarction. Thromb Haemost 109, 290–297 (2013).
van Montfoort, M. L. et al. Circulating nucleosomes and neutrophil activation as risk factors for deep vein thrombosis. Arterioscler Thromb Vasc Biol 33, 147–151 (2013).
Hirose, T. et al. Presence of neutrophil extracellular traps and citrullinated histone H3 in the bloodstream of critically ill patients. PLoS One 9, e111755 (2014).
Wong, S. L. et al. Diabetes primes neutrophils to undergo NETosis, which impairs wound healing. Nat Med 21, 815–819 (2015).
Demers, M. et al. Cancers predispose neutrophils to release extracellular DNA traps that contribute to cancer-associated thrombosis. Proc Natl Acad Sci USA 109, 13076–13081 (2012).
Maugeri, N. et al. Inhibition of tissue factor expression by hydroxyurea in polymorphonuclear leukocytes from patients with myeloproliferative disorders: a new effect for an old drug? J Thromb Haemost 4, 2593–2598 (2006).
Lapponi, M. J. et al. Regulation of neutrophil extracellular trap formation by anti-inflammatory drugs. J Pharmacol Exp Ther 345, 430–437 (2013).
Hurtado-Nedelec, M. et al. Increased reactive oxygen species production and p47phox phosphorylation in neutrophils from myeloproliferative disorders patients with JAK2 (V617F) mutation. Haematologica 98, 1517–1524 (2013).
Vaidya, R. et al. Plasma cytokines in polycythemia vera: phenotypic correlates, prognostic relevance, and comparison with myelofibrosis. Am J Hematol 87, 1003–1005 (2012).
Sur Chowdhury, C. et al. Enhanced neutrophil extracellular trap generation in rheumatoid arthritis: analysis of underlying signal transduction pathways and potential diagnostic utility. Arthritis Res Ther. 16, R122 (2014).
Hashiba, M. et al. Neutrophil extracellular traps in patients with sepsis. J Surg Res 194, 248–254 (2015).
Etulain, J. et al. P-selectin promotes neutrophil extracellular trap formation in mice. Blood 126, 242–246 (2015).
Hakkim, A. et al. Activation of the Raf-MEK-ERK pathway is required for neutrophil extracellular trap formation. Nat Chem Biol 7, 75–77 (2011).
Gangat, N. et al. DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol 29, 392–397 (2011).
Borissoff, J. I. et al. Elevated levels of circulating DNA and chromatin are independently associated with severe coronary atherosclerosis and a prothrombotic state. Arterioscler Thromb Vasc Biol 33, 2032–2040 (2013).
Marty, C. et al. A role for reactive oxygen species in JAK2V617F myeloproliferative neoplasm progression. Leukemia 27, 2187–2195 (2013).
Kagoya, Y. et al. JAK2V617F+ myeloproliferative neoplasm clones evoke paracrine DNA damage to adjacent normal cells through secretion of lipocalin-2. Blood 124, 2996–3006 (2014).
Rampal, R. et al. Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis. Blood 123, e123–133 (2014).
Remijsen, Q. et al. Neutrophil extracellular trap cell death requires both autophagy and superoxide generation. Cell Res 21, 290–304 (2011).
Wolach, B., Gavrieli, R., Manor, Y. & Lishner, M. Leukocyte function in chronic myeloproliferative disorders. Blood Cells Mol Dis 24, 544–551 (1998).
Chen, R., Kang, R., Fan, X. G. & Tang, D. Release and activity of histone in diseases. Cell Death Dis 5, e1370 (2014).
Holdenrieder, S. et al. Nucleosomes in serum of patients with benign and malignant diseases. Int J Cancer 95, 114–120 (2001).
Gould, T. J., Lysov, Z. & Liaw, P. C. Extracellular DNA and histones: double-edged swords in immunothrombosis. J Thromb Haemost 13, Suppl 1 S82–91 (2015).
Alhamdi, Y. & Toh, C. H. The role of extracellular histones in haematological disorders. Br J Haematol 173, 805–811 (2016).
Allam, R. et al. Histones from dying renal cells aggravate kidney injury via TLR2 and TLR4. J Am Soc Nephrol 23, 1375–1388 (2012).
Verstovsek, S. et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med 363, 1117–1127 (2010).
Vardiman, J. W. et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 114, 937–951 (2009).
Thomas, G. M. et al. Extracellular DNA traps are associated with the pathogenesis of TRALI in humans and mice. Blood 119, 6335–6343 (2012).
Fuchs, T. A. et al. Neutrophils release extracellular DNA traps during storage of red blood cell units. Transfusion 53, 3210–3216 (2013).
Etulain, J. et al. Acidosis downregulates platelet haemostatic functions and promotes neutrophil proinflammatory responses mediated by platelets. Thromb Haemost 107, 99–110 (2012).
Heller, P. G. et al. JAK2V617F mutation in platelets from essential thrombocythemia patients: correlation with clinical features and analysis of STAT5 phosphorylation status. Eur J Haematol 77, 210–216 (2006).
Glembotsky, A. C. et al. Screening for MPL mutations in essential thrombocythemia and primary myelofibrosis: normal Mpl expression and absence of constitutive STAT3 and STAT5 activation in MPLW515L-positive platelets. Eur J Haematol 84, 398–405 (2010).
Mela Osorio, M. J. et al. Long-term follow-up of essential thrombocythemia patients treated with anagrelide: subgroup analysis according to JAK2/CALR/MPL mutational status. Eur J Haematol 96, 435–442 (2016).
Acknowledgements
The authors would like to thank Nora P. Goette for intellectual input and critical reading of the manuscript, Gabriel Correa for measurement of D-dimer levels and Verónica Cortés Guerrieri and Victoria Caula for referral of patient samples. This work was supported by research grants from the National Agency for Scientific and Technological Research Promotion (ANPCyT) to M.S. and P.G.H., PICT 14-0352 and PICT 12-0629, respectively.
Author information
Authors and Affiliations
Contributions
C.P.M.O. designed and performed experiments, interpreted data and drafted the manuscript; A.C. designed and performed experiments, discussed results and prepared figures; P.R.L., A.C.G., R.F.M. designed and performed experiments and discussed results; M.A.C.R., B.M., F.C.M. and P.G.H. provided patient samples and clinical data; P.G.H. and M.S. jointly designed and supervised the study, interpreted data and wrote the paper. All authors contributed to manuscript editing and final approval.
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Electronic supplementary material
Rights and permissions
This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
About this article
Cite this article
Marin Oyarzún, C., Carestia, A., Lev, P. et al. Neutrophil extracellular trap formation and circulating nucleosomes in patients with chronic myeloproliferative neoplasms. Sci Rep 6, 38738 (2016). https://doi.org/10.1038/srep38738
Received:
Accepted:
Published:
DOI: https://doi.org/10.1038/srep38738
This article is cited by
-
ROP-ET: a prospective phase III trial investigating the efficacy and safety of ropeginterferon alfa-2b in essential thrombocythemia patients with limited treatment options
Annals of Hematology (2024)
-
The role of Extracellular Genomic Materials (EGMs) in psychiatric disorders
Translational Psychiatry (2023)
-
Octyl gallate decrease lymphocyte activation and regulates neutrophil extracellular traps release
Molecular Biology Reports (2022)
-
Stromal-driven and Amyloid β-dependent induction of neutrophil extracellular traps modulates tumor growth
Nature Communications (2021)
-
Pathogenesis of cardiovascular events in BCR-ABL1-negative myeloproliferative neoplasms
Leukemia (2021)
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.